Debilitating and lethal infections resulting from routine surgeries have become a serious medical problem." -- Stephen Chubb
Past News ReleasesRSS
Rochester, NY (PRWEB) June 22, 2011
Codevax, Inc. a U.S. privately held emerging vaccine company announced today the election of Stephen D. Chubb to its Board of Directors. Codevax, a technology transfer partner with the University of Rochester Medical Center (URMC) is developing immunizations and treatments for hospital-acquired infections, specifically MRSA and osteomyelitis from bone and joint replacements.
“We are very pleased to announce Steve’s addition to the board,” said Steve Dewhurst, PhD., Codevax Chairman and President, and Chair of Microbiology and Immunology. “Steve is without a doubt a well respected entrepreneur and has keen business acumen. We are excited about the contribution he will make to our business strategy and strategic growth plans for immunotherapy of infectious diseases - specifically MRSA prevention and treatment.”
Chubb is a seasoned executive with more than 30 years of experience in the medical devices and biotechnology industries. He is currently a business advisor to Catalyst Healthcare Ventures, LLP and a Director on the boards of Allegro Diagnostics Corp., Immunetics, Inc., and Charles River Laboratories International. Chubb is the former Chairman of the Board to Mount Auburn Hospital, Cambridge, MA.
"Debilitating and lethal infections resulting from routine surgeries have become a serious medical problem," said Chubb."Codevax has been supporting researchers at the University of Rochester Medical School, who have identified particularly susceptible targets on the most pernicious of these infection causing organisms and are working on a vaccine to eliminate them. It is a privilege to be associated with Codevax in assisting the company in bringing this important therapy to market quickly."
Previously, Chubb was the Chairman and Chief Executive Officer of Matritech, Inc., a proteomics-based diagnostics company for the early detection of bladder cancer. Earlier in his career, he was President and Chief Executive Officer of T Cell Sciences, Inc.; President of the Hyland Diagnostics Division at Baxter Corporation; and President and Chief Executive Officer of Cytogen Corp. Chubb is a Certified Public Accountant, holds an M.B.A. from the Kellogg School of Management at Northwestern University and is a graduate of the U.S. Naval Academy.
This announcement coincides with the launching of Codevax’s updated corporate website, http://www.codevax.com. MRSA research based on presentations by URMC scientists at the 2011 Orthopedic Research Society meeting (http://www.urmc.rochester.edu/news/story/index.cfm?id=3095) is now posted on the website. URMC orthopedic scientists, working in collaboration with Codevax, announced at the meeting that they are closer to developing a vaccine for life-threatening MRSA bacterial infections.
MRSA vaccine research by other investigators has failed to produce a viable option for patients because of the inability to identify an agent that can break through the deadly bacteria’s unique armor. Most other research has targeted the surface of the bacteria, but the URMC team has discovered an antibody that reaches beyond the microbe’s surface and can stop the MRSA bacterium from growing.
Codevax, Inc. is a vaccine company focused on developing immunizations and treatments for hospital acquired infections with emphasis on MRSA infections and osteomyelitis associated with bone and joint replacement surgery. Codevax has a parallel research program targeting another challenging hospital-acquired infection, Acinetobacter baumannii. The MRSA immunotherapy work is supported by an SBIR grant from the National Institutes of Health (NIH) and funding from a Qualifying Therapeutic Discovery Grant. Established in 2008, Codevax is a US privately held company with an R&D partnership with the University of Rochester Medical Center (URMC). The company is founded on and has access to the pioneering research in vaccine development, and expertise in infectious diseases and immunology, of URMC scientists. Codevax is committed to expanding beyond its pre-clinical research to rapidly develop and commercialize prophylactic and therapeutic vaccines against infectious diseases.